ATE522226T1 - Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms - Google Patents

Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms

Info

Publication number: ATE522226T1
Authority: AT; Austria
Prior art keywords: methods; syndrome; ovarial; compositions; treating polycystic
Prior art date: 2002-01-22

Application number

AT03703804T

Other languages

English (en)

Inventor

David Hathaway

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-22

Filing date

2003-01-14

Publication date

2011-09-15

2003-01-14 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2011-09-15 Application granted granted Critical

2011-09-15 Publication of ATE522226T1 publication Critical patent/ATE522226T1/de

Links

239000000203 mixture Substances 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
239000000556 agonist Substances 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT03703804T 2002-01-22 2003-01-14 Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms ATE522226T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US35039502P	2002-01-22	2002-01-22
US10/317,126 US7105489B2 (en)	2002-01-22	2002-12-11	Methods and compositions for treating polycystic ovary syndrome
PCT/US2003/001109 WO2003061362A2 (en)	2002-01-22	2003-01-14	Methods and compositions for treating polycystic ovary syndrome

Publications (1)

Publication Number	Publication Date
ATE522226T1 true ATE522226T1 (de)	2011-09-15

Family

ID=27616587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03703804T ATE522226T1 (de)	2002-01-22	2003-01-14	Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms

Country Status (10)

Country	Link
US (3)	US7105489B2 (de)
EP (1)	EP1523325B1 (de)
JP (1)	JP2005526712A (de)
AT (1)	ATE522226T1 (de)
AU (1)	AU2003205135B2 (de)
CA (1)	CA2473927C (de)
DK (1)	DK1523325T3 (de)
ES (1)	ES2372481T3 (de)
NZ (1)	NZ534611A (de)
WO (1)	WO2003061362A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1629849E (pt) *	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
US6703359B1 (en) *	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
KR100637433B1 (ko) *	2004-05-24	2006-10-20	삼성에스디아이 주식회사	발광 표시 장치
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
AUPR506601A0 (en) *	2001-05-17	2001-06-07	Australian National University, The	Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
US7105489B2 (en) *	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
EP1494732B1 (de)	2002-03-20	2008-01-30	MannKind Corporation	Inhalationsgerät
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006519229A (ja) *	2003-02-13	2006-08-24	アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ	視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
AU2004232858B2 (en)	2003-04-23	2009-07-09	Mannkind Corporation	Hydraulically actuated pump for long duration medicament administration
US8263084B2 (en) *	2003-11-13	2012-09-11	Hanmi Science Co., Ltd	Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (ko) *	2007-11-29	2012-04-24	한미사이언스 주식회사	인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20080015144A1 (en) *	2003-12-12	2008-01-17	Alvert Einstein College Of Medicine Of Yeshiva Uni	Glp- (9-36) Methods and Compositions
JP2006514649A (ja) *	2003-12-17	2006-05-11	アミリン・ファーマシューティカルズ，インコーポレイテッド	腎症の治療および予防のための組成物
US20080125403A1 (en) *	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006014425A1 (en) *	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
WO2006041922A2 (en) *	2004-10-08	2006-04-20	Dara Biosciences, Inc.	Agents and methods for administration to the central nervous system
US8716221B2 (en)	2005-01-14	2014-05-06	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
CA2603630C (en) *	2005-01-14	2015-06-09	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US20070026079A1 (en) *	2005-02-14	2007-02-01	Louis Herlands	Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
NZ561400A (en) *	2005-03-11	2010-02-26	Endo Pharmaceuticals Solutions	Controlled release formulations of octreotide
US7759312B2 (en) *	2005-03-11	2010-07-20	Endo Pharmaceuticals Solutions Inc.	Delivery of dry formulations of octreotide
ES2931949T3 (es) *	2005-03-29	2023-01-05	Univ Pennsylvania	Minoxidilo para generar nuevos folículos pilosos y tratar la calvicie
CA2606902A1 (en) *	2005-05-27	2006-11-30	Asubio Pharma Co., Ltd.	Insulin resistance improver
NZ565535A (en)	2005-06-30	2011-03-31	Ipsen Pharma Sas	GLP-1 pharmaceutical compositions
US20090202497A1 (en) *	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20070086972A1 (en) *	2005-09-12	2007-04-19	Jacob Birnbaum	Hair growth compositions and methods for treating hair loss or related conditions
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007056851A1 (en) *	2005-11-17	2007-05-24	Mount Sinai Hospital	Compositions and methods for enhancing ovulation inducing agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
AU2007233231B2 (en)	2006-03-30	2011-02-24	Mannkind Corporation	Multi-cartridge fluid delivery device
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DE102006026026A1 (de) *	2006-06-01	2007-12-06	Grünenthal GmbH	Arzneimittel
CA2670821C (en)	2006-08-09	2012-05-15	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
CA2683610C (en)	2007-04-23	2013-01-08	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
WO2009043478A2 (en) *	2007-09-11	2009-04-09	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
US20090186819A1 (en) *	2007-12-11	2009-07-23	Marieve Carrier	Formulation of insulinotropic peptide conjugates
WO2009102467A2 (en)	2008-02-13	2009-08-20	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009143285A2 (en) *	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (de)	2008-06-20	2021-12-29	MannKind Corporation	Interaktives Gerät für die Echtzeit-Profilierung von Inhalationsversuchen
UA104866C2 (uk) *	2008-06-25	2014-03-25	Ендо Фармас'Ютікалз Солюшнз Інк.	Імплантат октреотиду, який містить вивільняючу речовину
WO2009158412A2 (en)	2008-06-25	2009-12-30	Endo Pharmaceuticals Solutions Inc.	Sustained delivery of exenatide and other polypeptides
WO2010054326A2 (en)	2008-11-07	2010-05-14	The General Hospital Corporation	C-terminal fragments of glucagon-like peptide-1 (glp-1)
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP1-analoge pharmazeutische Zusammensetzungen
US9339458B2 (en) *	2009-02-18	2016-05-17	Itf Research Pharma, S.L.U.	Use of vaginal insulin sensitizing agents
ES2344183B1 (es) *	2009-02-18	2011-06-10	Italfarmaco, S.A.	Uso de agentes sensibilizantes a insulina por via vaginal.
MX378797B (es)	2009-09-28	2025-03-10	Intarcia Therapeutics Inc	Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
WO2012078649A1 (en)	2010-12-06	2012-06-14	Follica, Inc.	Methods for treating baldness and promoting hair growth
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2694402B1 (de)	2011-04-01	2017-03-22	MannKind Corporation	Blisterverpackung für pharmakartuschen
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
EP2729157B1 (de)	2011-07-06	2019-01-16	The General Hospital Corporation	Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
WO2013079560A1 (en)	2011-11-29	2013-06-06	Westfälische Wilhelms-Universität Münster	Genetic marker for polycystic ovary syndrome (pcos)
FI123665B (fi)	2012-02-20	2013-09-13	Raute Oyj	Menetelmä kaasugeneraattorin toiminnan optimoimiseksi ja kaasugeneraattori
EP2872205B1 (de)	2012-07-12	2017-02-08	MannKind Corporation	System zur verabreichung von arzneimitteln in trockenpulverform
WO2014018079A1 (en) *	2012-07-25	2014-01-30	University Of Cincinnati	Method of treating hyperglycemic disorders using apoliprotein aiv
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh)	2015-06-03	2021-11-05	因塔西亚制药公司	植入物放置和移除系统
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201518979D0 (en) *	2015-10-27	2015-12-09	Univ Leuven Kath	Treatment of hepatic steatosis related oligo-ovulation
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
WO2018129058A1 (en)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
BR112020010343A2 (pt) *	2017-11-23	2020-11-10	Biosearch, S.A.	método para aumentar taxa de implantação de embrião em um paciente feminino sofrendo de síndrome de ovário policístico
IL305952A (en)	2021-03-19	2023-11-01	Crinetics Pharmaceuticals Inc	Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
WO2023163945A1 (en) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
CN114656524B (zh) *	2022-03-31	2023-12-26	深圳先进技术研究院	一种靶向卵巢多肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
PT1629849E (pt)	1997-01-07	2013-07-09	Amylin Pharmaceuticals Llc	Composições farmacêuticas que compreendem exendinas e seus agonistas
DK1019077T4 (da) *	1997-08-08	2011-03-07	Amylin Pharmaceuticals Inc	Hidtil ukendte exendinagonistforbindelser
KR20010043455A (ko)	1998-06-30	2001-05-25	다케다 야쿠힌 고교 가부시키가이샤	당뇨병 치료용 약학적 조성물
ATE272633T1 (de) *	1998-12-23	2004-08-15	Lilly Co Eli	Aromatische amiden
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
US6569901B2 (en) *	2000-01-28	2003-05-27	Novo Nordisk A/S	Alkynyl-substituted propionic acid derivatives, their preparation and use
ATE266409T1 (de) *	2000-04-13	2004-05-15	Pfizer Prod Inc	Synergistische wirkung von glyburide und milrinone
WO2002085406A1 (en) *	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
US7105489B2 (en) *	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
AU2003205926A1 (en)	2002-02-07	2003-09-02	Pfizer Limited	Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
AU2003283216A1 (en)	2002-12-03	2004-06-23	Novo Nordisk A/S	Combination treatment using exendin-4 and thiazolidinediones

2002
- 2002-12-11 US US10/317,126 patent/US7105489B2/en not_active Expired - Fee Related
2003
- 2003-01-14 JP JP2003561318A patent/JP2005526712A/ja active Pending
- 2003-01-14 DK DK03703804.9T patent/DK1523325T3/da active
- 2003-01-14 AT AT03703804T patent/ATE522226T1/de not_active IP Right Cessation
- 2003-01-14 NZ NZ534611A patent/NZ534611A/en not_active IP Right Cessation
- 2003-01-14 EP EP03703804A patent/EP1523325B1/de not_active Expired - Lifetime
- 2003-01-14 AU AU2003205135A patent/AU2003205135B2/en not_active Ceased
- 2003-01-14 WO PCT/US2003/001109 patent/WO2003061362A2/en not_active Ceased
- 2003-01-14 ES ES03703804T patent/ES2372481T3/es not_active Expired - Lifetime
- 2003-01-14 CA CA2473927A patent/CA2473927C/en not_active Expired - Fee Related
- 2003-07-30 US US10/629,649 patent/US7105490B2/en not_active Expired - Fee Related
2006
- 2006-09-08 US US11/518,574 patent/US7960341B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7105490B2 (en)	2006-09-12
EP1523325A4 (de)	2007-02-21
JP2005526712A (ja)	2005-09-08
US20070066528A1 (en)	2007-03-22
WO2003061362A2 (en)	2003-07-31
CA2473927C (en)	2013-03-12
NZ534611A (en)	2008-04-30
WO2003061362A3 (en)	2005-02-24
US20040266678A1 (en)	2004-12-30
EP1523325B1 (de)	2011-08-31
EP1523325A2 (de)	2005-04-20
AU2003205135B2 (en)	2008-01-17
US20040029784A1 (en)	2004-02-12
DK1523325T3 (da)	2011-11-21
CA2473927A1 (en)	2003-07-31
US7105489B2 (en)	2006-09-12
US7960341B2 (en)	2011-06-14
ES2372481T3 (es)	2012-01-20

Legal Events

Date	Code	Title	Description
2012-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
MY127961A (en)	2007-01-31	Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
DE60330485D1 (de)	2010-01-21	Zur behandlung von diabetes
ATE394423T1 (de)	2008-05-15	Analoge des glucagon ähnlichen peptides-1 (glp-1)
DE60310991D1 (de)	2007-02-15	Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
UA86599C2 (en)	2009-05-12	Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
DK1556362T3 (da)	2008-06-09	Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
ATE395912T1 (de)	2008-06-15	Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
ATE417832T1 (de)	2009-01-15	Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes
DE60110054D1 (en)	2005-05-19	Cardioprotektive phosphonate
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
ATE549926T1 (de)	2012-04-15	Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
EA200500782A1 (ru)	2005-10-27	Лечение геморрагического шока
EA200601554A1 (ru)	2006-12-29	Замещенные индол-о-глюкозиды
ATE411280T1 (de)	2008-10-15	Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
ATE521357T1 (de)	2011-09-15	Verfahren zur behandlung von hepatitis
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
DE60140871D1 (de)	2010-02-04	Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DK1651270T3 (da)	2007-07-16	Medikamenter til inhalation omfattende betamimetika og et anticholinergikum
EA200601279A1 (ru)	2006-12-29	Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
CY1105721T1 (el)	2010-12-22	Δερματικοι αναισθητικοι παραγοντες
MXPA04002539A (es)	2004-05-31	Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
CY1105822T1 (el)	2011-02-02	Χρηση αντιδιαβητικων παραγοντων για την κατασκευη ενος φαρμακου που εχει επουλωτικη δραση
DE60216979D1 (de)	2007-02-01	Synergistische zusammensetzung aus trans-tetracos-15-ensäure und apocynin, und verwendung davon